98%
921
2 minutes
20
Psoriasis is a common skin disorder that needs a long-term management, not only because, of its prevalence but also because of the profound impact it can have on patients quality of life. Drugs may result in exacerbation of a preexisting psoriasis, in induction of psoriatic lesions on clinically uninvolved skin in patients with psoriasis, or in precipitation of the disease in persons without family history of psoriasis or in predisposed individuals. The knowledge of the drugs that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice. By reviewing the literature, there are many reports on drug-induced psoriasis, but the data are not univocal. We propose, when possible, the use of a probability score from the authors to obtain a better classification and further understanding of drug-induced psoriasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15569520500536568 | DOI Listing |
Sci Rep
August 2025
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Drug-induced liver injury (DILI) represents a major clinical challenge, often limiting the therapeutic use of agents such as acitretin, a second-generation retinoid prescribed for psoriasis. This study established and characterized a rat model of acitretin-induced hepatotoxicity, aiming to explore potential biomarkers and mechanisms of protection. Fifty male Sprague-Dawley rats were divided into five groups: control, acitretin, melatonin + acitretin, naringenin + acitretin, and combination treatment.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
August 2025
Department of Clinical Pharmacy, Zibo Central Hospital, Zibo, Shandong, China.
Introduction: Some cases report that beta-blockers may induce or exacerbate psoriasis. However, pharmacoepidemiology studies have yielded conflicting results. This study aims to investigate whether there is a potential association between beta-blockers and psoriasis.
View Article and Find Full Text PDFJ Nippon Med Sch
August 2025
Division of Dermatology, Nippon Medical School Musashi Kosugi Hospital.
Psoriasis is a condition characterized by chronic inflammation of the skin, epidermal hyperproliferation, and dysregulated differentiation driven by acceleration of the tumor necrosis factor-alpha/interleukin (IL) -23/IL-17 axis. Herein, we report a case of generalized pustular psoriasis initially managed with etretinate, apremilast, and risankizumab in a Japanese man. Because of side effects, a therapeutic transition was made to brodalumab at 7 months after the initial consultation.
View Article and Find Full Text PDFCureus
July 2025
Internal Medicine, RWJBarnabas Health Community Medical Center, Toms River, USA.
Understanding unintentional and adverse reactions to medications is key in pharmacologic therapy. These adverse effects can range from mild, well-tolerated symptoms to detrimental consequences for the patient. These symptoms can also range in terms of organ system involvement, some of which may be isolated to only the skin, while others can create end-organ damage and involve multiple systems.
View Article and Find Full Text PDFJ Cutan Med Surg
August 2025
Department of Dermatology, McMaster University, Hamilton, ON, Canada.